Approved treatment — U.S. FDA (2026-10-07), maintenance for HER2-positive metastatic breast cancer Japan — tucatinib approved for use after prior therapy (2026-02); maintenance use not included
HER2-positive breast cancer maintenance therapy has a new option. On October 7, 2026, the U.S. FDA approved the oral targeted drug tucatinib (brand name Tukysa) together with trastuzumab and pertuzumab as maintenance treatment for adults with unresectable or metastatic HER2-positive breast cancer whose disease did not progress after first-line induction treatment. In the phase 3 HER2CLIMB-05 trial behind the approval, median progression-free survival was 24.9 months, 8.6 months longer than the 16.3 months with placebo.
What was newly approved: an oral targeted drug added during maintenance
First-line treatment for HER2-positive metastatic breast cancer usually combines two anti-HER2 antibodies, trastuzumab (Herceptin) and pertuzumab (Perjeta), with a taxane chemotherapy for several months. This is called induction treatment. When the disease is well controlled, chemotherapy is often stopped and patients continue with the two antibodies alone as maintenance therapy. The aim of maintenance is to keep the disease from growing for as long as possible while reducing the burden of chemotherapy.
The new approval adds tucatinib tablets, 300 mg twice a day, during this maintenance phase. Tucatinib is a tyrosine kinase inhibitor (TKI) that blocks HER2 signaling from inside the cell, while the antibodies bind HER2 on the outside, so combining them has been studied as a strategy. In the U.S., tucatinib has been used since 2020 with trastuzumab and capecitabine for metastatic breast cancer after prior anti-HER2 treatment, including patients with brain metastases. This approval extends its use to an earlier stage.
Trastuzumab and pertuzumab can be given intravenously or as a combined subcutaneous injection. In the trial, patients with hormone receptor-positive disease could continue endocrine (hormone) therapy. Treatment continues until the disease progresses or side effects become unacceptable.
Who it is for: HER2-positive patients stable after induction
Based on the FDA label wording and trial criteria, it is for adults who meet all of the following:
- Breast cancer confirmed as HER2-positive on tissue testing
- Unresectable locally advanced or metastatic disease
- No disease progression after 4 to 8 cycles of induction with trastuzumab, pertuzumab and a taxane
A wide range of patients took part. 69.3% had metastatic disease at first diagnosis, 52.6% were hormone receptor-positive, and 12.4% had current or previous brain metastases. The median age was 54. Researchers from Japan were among the authors of this international trial.
HER2CLIMB-05 results: 8.6 more months without progression
The evidence comes from HER2CLIMB-05 (NCT05132582), a randomized, double-blind, placebo-controlled phase 3 trial. From March 2022 to July 2024, 654 patients were assigned to tucatinib (326) or placebo (328); both groups continued trastuzumab and pertuzumab. Results were published in the Journal of Clinical Oncology (JCO) in December 2025 and presented at the San Antonio Breast Cancer Symposium (SABCS).
| Measure | Tucatinib + two antibodies | Placebo + two antibodies |
|---|---|---|
| Median progression-free survival (overall) | 24.9 months | 16.3 months |
| Hazard ratio for progression or death | 0.64 (95% CI 0.51–0.80) — 35.9% lower risk | |
| Hormone receptor-negative | 24.9 months | 12.6 months |
| Hormone receptor-positive | 25.0 months | 18.1 months |
| Grade 3 or higher adverse events | 42.3% | 24.4% |
Sources: U.S. FDA approval notice (2026-10-07), Diéras V et al., JCO 2025, The ASCO Post report of March 2026 (hormone receptor subgroups). PFS was assessed by investigators.
The benefit pointed in the same direction in all prespecified subgroups (de novo or recurrent disease, hormone receptor-positive or -negative, with or without brain metastases, under or over 65). The difference was especially large in hormone receptor-negative patients (hazard ratio 0.554). In an exploratory analysis of patients with brain metastases, the median time without progression in the brain rose from 4.3 to 8.5 months. Overall survival is at an early stage, with about 20% of the required events; it shows a numerical trend favoring tucatinib, and follow-up continues.
Side effects and management: watch for diarrhea and liver tests
Common side effects with tucatinib were diarrhea (72.7%; grade 3 or higher 6.1%), nausea (33.1%) and raised liver enzymes (ALT 28.2%, AST 25.8%). The most frequent grade 3 or higher events were ALT increase (13.5%) and AST increase (7.1%), which were mostly symptom-free, temporary and reversible with dose changes. 13.5% of patients stopped tucatinib because of side effects.
The FDA label carries a boxed warning for liver toxicity, so regular blood tests of liver function are part of treatment. Diarrhea is managed with antidiarrheal medicine, fluids and, when needed, dose adjustment. Blood creatinine can rise without any effect on kidney function, and because the drug can harm a fetus, contraception is needed during treatment.
Where it is available: approved in the U.S.; approved for another stage in Japan
- United States: the FDA approved the maintenance use on October 7, 2026 (approved treatment).
- Japan: tucatinib (Japanese brand name Tukaiza) was approved on February 19, 2026 and launched on April 21, 2026. Its Japanese approval covers HER2-positive unresectable or recurrent breast cancer previously treated with chemotherapy, in combination with trastuzumab and capecitabine. As of the date checked, first-line maintenance use is not included.
- Other countries: according to Pfizer, tucatinib is approved in more than 50 countries, mostly for use after prior treatment. Approval for maintenance use needs to be checked country by country.
Use outside the approved indication may not be covered by insurance, so if you are considering treatment abroad, first check the approved scope and cost in that country. You can read how to approach information published by Japanese medical institutions in Other Japanese medical information.
What patients should check — questions for your doctor
- Does my induction result count as “no progression”? Is it time to move to maintenance?
- Given my hormone receptor status, how much benefit could adding tucatinib bring?
- Should I have a brain MRI to check for brain metastases?
- How often will my liver function be tested, and what should I do if diarrhea starts?
- Do any of my current medicines or supplements interact with tucatinib?
Frequently asked questions
What is maintenance therapy for HER2-positive breast cancer?
It is the phase after first-line chemotherapy has controlled the disease, when chemotherapy is stopped and anti-HER2 treatment such as trastuzumab and pertuzumab continues to keep the disease stable for longer. This approval adds the oral drug tucatinib to that phase.
How much does adding tucatinib help?
In HER2CLIMB-05, median time without progression was 24.9 months, 8.6 months longer than 16.3 months with placebo. Follow-up for overall survival is ongoing.
What are the side effects of tucatinib?
Diarrhea, nausea and raised liver enzymes were common. Liver enzyme rises were mostly symptom-free and improved with dose changes, and they are monitored with regular blood tests.
Can I receive this maintenance treatment in Japan?
Tucatinib was approved in Japan in February 2026, but for use after prior chemotherapy. As of the date checked (2026-10-19), first-line maintenance use is not within the Japanese approval, so check PMDA or Pfizer announcements for the latest status.
Related: FDA approves atezolizumab for stage III dMMR colon cancer · CAR-NK vs CAR-T · All articles by cancer type
Sources
- U.S. FDA — FDA approves tucatinib with trastuzumab and pertuzumab for the maintenance treatment of HER2-positive breast cancer (2026-10-07)
fda.gov
Checked: 2026-10-19 - Diéras V, Curigliano G, Martin M, et al. HER2CLIMB-05: a phase III study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as first-line maintenance therapy for HER2+ metastatic breast cancer. J Clin Oncol 2025 (PMID 41369677)
pubmed.ncbi.nlm.nih.gov/41369677
Checked: 2026-10-19 - Pfizer — TUKYSA added to first-line maintenance therapy extends median progression-free survival by over 8 months (2025-12-10)
pfizer.com
Checked: 2026-10-19 - The ASCO Post — Adding tucatinib to first-line maintenance therapy delays disease progression in HER2-positive metastatic breast cancer (2026-03-25)
ascopost.com
Checked: 2026-10-19 - CareNet — Launch of tucatinib (Japanese brand name Tukaiza) in Japan (2026-04-22, Japanese-language source)
carenet.com
Checked: 2026-10-19
Written by the FTH editorial team. Sources checked 2026-10-19 · Medical review: not applicable
This article is general information based on public sources and does not replace diagnosis or treatment. Please discuss treatment decisions with your medical team.
